Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Trial of Combined Weekly Bortezomib (VELCADE) and Y-90-Ibritumomab Tiuxetan (Zevalin) in Patients With Relapsed or Refractory Follicular Lymphoma and Transformed Non-Hodgkin's Lymphoma.

Trial Profile

A Phase I/II Trial of Combined Weekly Bortezomib (VELCADE) and Y-90-Ibritumomab Tiuxetan (Zevalin) in Patients With Relapsed or Refractory Follicular Lymphoma and Transformed Non-Hodgkin's Lymphoma.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 24 Oct 2018

At a glance

  • Drugs Bortezomib (Primary) ; Ibritumomab tiuxetan; Rituximab
  • Indications Follicular lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Sep 2018 Status changed from active, no longer recruiting to discontinued before the accrual goal was met due to slow accrual
    • 15 Mar 2017 Planned End Date changed from 1 Aug 2016 to 1 Aug 2020.
    • 15 Mar 2017 Planned primary completion date changed from 1 Aug 2015 to 1 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top